SCHEMBL29460215

SCHEMBL29460215

O=C(NC12CC(C(F)(F)F)(C1)C2)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ APAF1 O14727 1/20 0.49
▸ TDP2 O95551 1/20 0.49
▸ NSD2 O96028 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ GALK1 P51570 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ CES2 O00748 1/20 0.47
▸ CES1 P23141 1/20 0.47
▸ NPC1 O15118 1/20 0.44
▸ CRHBP P24387 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ CRHR2 Q13324 1/20 0.44
▸ TRPV1 Q8NER1 2/20 0.43
▸ PTGS1 P23219 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31046923 0.87 IDO1 (0.46) KDM4EKMT2ANPC1RAB9A
SCHEMBL29460253 0.86 KDM4E (0.48) KDM4EAPAF1TDP2NSD2MAPT
SCHEMBL23141420 0.85 FAAH (0.53) KDM4EAPAF1TDP2NSD2MAPT
SCHEMBL23141427 0.85 KDM4E (0.50) KDM4EAPAF1TDP2NSD2MAPT
SCHEMBL29460251 0.84 NPSR1 (0.52) MAPTKMT2ACES2RAB9APTGS1
SCHEMBL29460292 0.82 TRPV1 (0.49) NPC1RAB9ATRPV1
SCHEMBL23141335 0.80 KDM4E (0.46) KDM4EAPAF1TDP2NSD2MAPT
SCHEMBL29460313 0.80 IDO1 (0.52) CASP3SENP8SENP7SENP6CES2
SCHEMBL23141350 0.79 KDM4E (0.51) KDM4EAPAF1TDP2NSD2MAPT
SCHEMBL23877431 0.79 CES2 (0.38) CES2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
CN-118791407-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-10-18 — — CN disclosed
CN-118638096-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-09-13 — — CN disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 — — CN disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B KDM4E 3158/4885APAF1 3862/4885TDP2 4269/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B KDM4E 3158/4885APAF1 3862/4885TDP2 4269/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 KDM4E 3921/4885APAF1 4880/4885TDP2 4091/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B KDM4E 3158/4885APAF1 3862/4885TDP2 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback